Northern Trust Corp bought a new stake in Beyondspring Inc (NASDAQ:BYSI) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 30,382 shares of the company’s stock, valued at approximately $720,000. Northern Trust Corp owned 0.14% of Beyondspring at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Strs Ohio purchased a new stake in shares of Beyondspring in the second quarter valued at $68,000. JPMorgan Chase & Co. purchased a new stake in shares of Beyondspring in the second quarter valued at $66,000. Wells Fargo & Company MN purchased a new stake in shares of Beyondspring in the second quarter valued at $439,000. Bank of New York Mellon Corp purchased a new stake in shares of Beyondspring in the second quarter valued at $516,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in shares of Beyondspring in the second quarter valued at $528,000. 5.27% of the stock is currently owned by institutional investors and hedge funds.

BYSI has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $41.00 price target on shares of Beyondspring in a research note on Wednesday, September 18th. Zacks Investment Research downgraded shares of Beyondspring from a “buy” rating to a “hold” rating in a research note on Thursday. Finally, ValuEngine downgraded shares of Beyondspring from a “buy” rating to a “hold” rating in a research note on Wednesday.

BYSI stock opened at $17.00 on Friday. Beyondspring Inc has a 12 month low of $13.06 and a 12 month high of $25.79. The firm’s 50-day moving average is $18.37 and its 200 day moving average is $17.41.

Beyondspring (NASDAQ:BYSI) last posted its quarterly earnings results on Wednesday, September 18th. The company reported ($0.32) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by ($0.05). On average, equities research analysts expect that Beyondspring Inc will post -1.54 EPS for the current fiscal year.

Beyondspring Company Profile

BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.

See Also: Back-End Load

Institutional Ownership by Quarter for Beyondspring (NASDAQ:BYSI)

Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.